Form 4: Director Cheryl Scott Reports Acquisition and Disposal of Progyny, Inc. Securities

Cheryl Scott, a director of Progyny, Inc., reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On May 23, 2024, Cheryl Scott, a director of Progyny, Inc., filed a Form 4 indicating changes in beneficial ownership of the company's securities.
• Scott acquired 5,147 shares of common stock underlying restricted stock units (RSUs) at a price of $0, which will vest on May 23, 2025, contingent upon continued service.
• She also acquired options to purchase 23,212 shares of common stock at an exercise price of $27.15, vesting on May 23, 2025, also contingent upon continued service, and expiring on May 22, 2034.
• Additionally, Scott disposed of 11,560 shares of common stock.
• Following these transactions, Scott beneficially owns 23,212 derivative securities and 11,560 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but the acquisition of shares and options could be mildly positive, while the disposal is mildly negative. The overall sentiment is neutral.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 11,560 shares of common stock by a director could be interpreted negatively, although the reason for the disposal is not specified.

Risks

• The vesting of RSUs and stock options is contingent upon the director's continued service, creating a potential risk if the director were to leave the company before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs and stock options in 2025 suggests an expectation of continued service and potential future value.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings of company stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are made by directors and officers of companies like Teladoc Health (TDOC) and UnitedHealth Group (UNH) when they trade company stock.
• The vesting schedules and exercise prices of stock options are generally aligned with industry norms for executive compensation.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company directors as an indicator of confidence in the company's prospects.

Key Dates